2/27
02:22 pm
xene
Xenon Pharmaceuticals (XENE) had its price target raised by Needham & Company LLC from $55.00 to $58.00. They now have a "buy" rating on the stock.
Low
Report
Xenon Pharmaceuticals (XENE) had its price target raised by Needham & Company LLC from $55.00 to $58.00. They now have a "buy" rating on the stock.
2/27
11:41 am
xene
Xenon Pharmaceuticals (XENE) had its price target raised by Wells Fargo & Company from $48.00 to $49.00. They now have an "overweight" rating on the stock.
Low
Report
Xenon Pharmaceuticals (XENE) had its price target raised by Wells Fargo & Company from $48.00 to $49.00. They now have an "overweight" rating on the stock.
2/26
05:14 pm
xene
Xenon Pharmaceuticals: Q4 Earnings Snapshot [Yahoo! Finance]
Low
Report
Xenon Pharmaceuticals: Q4 Earnings Snapshot [Yahoo! Finance]
2/26
04:01 pm
xene
Xenon Reports Q4 and Full Year 2025 Financial Results and Provides Business Update
Low
Report
Xenon Reports Q4 and Full Year 2025 Financial Results and Provides Business Update
2/26
12:56 am
xene
Xenon Pharmaceuticals Stock Scores RS Rating Upgrade [Yahoo! Finance]
Low
Report
Xenon Pharmaceuticals Stock Scores RS Rating Upgrade [Yahoo! Finance]
2/25
06:24 am
xene
Xenon Pharmaceuticals (XENE) was upgraded by Wolfe Research to "strong-buy".
Low
Report
Xenon Pharmaceuticals (XENE) was upgraded by Wolfe Research to "strong-buy".
2/23
06:01 pm
xene
Xenon Pharmaceuticals (NASDAQ:XENE) is now covered by analysts at Wolfe Research. They set an "outperform" rating on the stock.
Low
Report
Xenon Pharmaceuticals (NASDAQ:XENE) is now covered by analysts at Wolfe Research. They set an "outperform" rating on the stock.
2/10
09:03 am
xene
Xenon Pharmaceuticals (NASDAQ:XENE) was given a new $66.00 price target on by analysts at Stifel Nicolaus.
Low
Report
Xenon Pharmaceuticals (NASDAQ:XENE) was given a new $66.00 price target on by analysts at Stifel Nicolaus.
1/16
04:05 pm
xene
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
1/13
04:06 am
xene
Xenon Pharmaceuticals (NASDAQ:XENE) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Xenon Pharmaceuticals (NASDAQ:XENE) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
1/12
08:30 am
xene
Xenon Outlines Key Upcoming Milestones at the 2026 J.P. Morgan Healthcare Conference
Medium
Report
Xenon Outlines Key Upcoming Milestones at the 2026 J.P. Morgan Healthcare Conference
1/9
08:02 am
xene
Xenon Pharmaceuticals (NASDAQ:XENE) had its price target raised by analysts at JPMorgan Chase & Co. from $60.00 to $62.00. They now have an "overweight" rating on the stock.
Low
Report
Xenon Pharmaceuticals (NASDAQ:XENE) had its price target raised by analysts at JPMorgan Chase & Co. from $60.00 to $62.00. They now have an "overweight" rating on the stock.
1/5
09:28 am
xene
Xenon to Present at the 44th Annual J.P. Morgan Healthcare Conference [Canadian Business Journal (Canada)]
Medium
Report
Xenon to Present at the 44th Annual J.P. Morgan Healthcare Conference [Canadian Business Journal (Canada)]
1/5
08:41 am
xene
Xenon to Present at the 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]
Medium
Report
Xenon to Present at the 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]
1/5
08:30 am
xene
Xenon to Present at the 44th Annual J.P. Morgan Healthcare Conference
Low
Report
Xenon to Present at the 44th Annual J.P. Morgan Healthcare Conference
12/11
12:31 pm
xene
Xenon Pharmaceuticals (NASDAQ:XENE) had its price target raised by analysts at Wells Fargo & Company from $44.00 to $48.00. They now have an "overweight" rating on the stock.
Low
Report
Xenon Pharmaceuticals (NASDAQ:XENE) had its price target raised by analysts at Wells Fargo & Company from $44.00 to $48.00. They now have an "overweight" rating on the stock.
12/5
09:28 am
xene
Xenon Showcases New 48-Month Azetukalner OLE Study Data in Epilepsy at AES 2025 [Canadian Business Journal (Canada)]
Low
Report
Xenon Showcases New 48-Month Azetukalner OLE Study Data in Epilepsy at AES 2025 [Canadian Business Journal (Canada)]
12/5
09:00 am
xene
Xenon Showcases New 48-Month Azetukalner OLE Study Data in Epilepsy at AES 2025
Low
Report
Xenon Showcases New 48-Month Azetukalner OLE Study Data in Epilepsy at AES 2025
12/4
06:05 pm
xene
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
Low
Report
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
12/4
05:20 pm
xene
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
12/3
09:28 am
xene
Xenon Announces Investor Webinar Highlighting Azetukalner and Epilepsy Data from AES 2025 [Canadian Business Journal (Canada)]
Low
Report
Xenon Announces Investor Webinar Highlighting Azetukalner and Epilepsy Data from AES 2025 [Canadian Business Journal (Canada)]
12/3
09:12 am
xene
Xenon Announces Investor Webinar Highlighting Azetukalner and Epilepsy Data from AES 2025 [Yahoo! Finance]
Low
Report
Xenon Announces Investor Webinar Highlighting Azetukalner and Epilepsy Data from AES 2025 [Yahoo! Finance]
12/3
08:30 am
xene
Xenon Announces Investor Webinar Highlighting Azetukalner and Epilepsy Data from AES 2025
Low
Report
Xenon Announces Investor Webinar Highlighting Azetukalner and Epilepsy Data from AES 2025